What are your top takeaways in Cutaneous Malignancies from ASCO 2026?

I presented a phase II trial of neoadjuvant cemiplimab immunotherapy and response-adapted radiotherapy for patients with locally advanced, unresectable cutaneous squamous cell carcinoma. Historically, the 2-year progression-free survival (PFS) rate in this situation with radiotherapy with or without chemotherapy is ~40%. Recent data suggest that using anti-PD1 immunotherapy yields a 2-year PFS rate of ~50% in this situation, when patients have locally advanced cutaneous SCC that is not amenable ...

Two abstracts that stand out to me are Abstract 9500 (intismeran) and Abstract 9506 (radiotherapy plus cemipilimab for cutaneous squamous cell carcinoma).